poisar

Stock

Quantum Biopharma Ltd. Class B Subordinate Voting Shares QNTM

$3.13+1.29%

Overview

QNTM market data

Price History

QNTM price chart · 1M
O
3.14
H
3.14
L
3.09
C
3.13
Vol
1,310.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$3.14
Previous Close
$3.09
Day High
$3.14
Day Low
$3.09
52 Week High
$10.80
52 Week Low
$2.70
7 Day Return
-9.41%
30 Day Return
+1.13%
90 Day Return
-54.37%
1 Year Return
-44.75%
Daily Notional Volume
$4.1K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$7.97
Diluted earnings per share over the trailing twelve months.
Beta
5.36
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-9,078.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.85 – $28.59
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $30.7M · P/S 132.69.

Company News

9 captured
Quantum Biopharma shares are trading higher after the company announced it received FDA approval to proceed with its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis.Benzinga · Aug 14, 2026, 6:37 PM
Quantum BioPharma Says FDA Cleared IND For Lucid-MS Phase 2 Trial In Progressive Multiple Sclerosis; Reports Cash Runway To At Least October 2027Benzinga · Aug 14, 2026, 11:12 AM
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis TrialBenzinga · Aug 10, 2026, 10:31 AM
EXCLUSIVE: FDA Approves Quantum BioPharma's Lucid-MS Phase 2 Trial of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination For Progressive Multiple SclerosisBenzinga · Aug 10, 2026, 10:30 AM
Quantum BioPharma Announces Closing of Debt SettlementGlobenewswire Inc · Jul 30, 2026, 11:00 AM
Reported Earlier, Quantum BioPharma Approves Debt Settlement Of C$123,487.43 Via Class B Shares At Deemed Price Of C$4.26 Or LowerBenzinga · Jul 21, 2026, 6:53 AM
Quantum BioPharma Announces Intention to Settle DebtGlobenewswire Inc · Jul 20, 2026, 11:30 PM
Trading Halt: Halt status updated at 7:05:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jun 2, 2026, 11:05 AM
Trading Halt: Halted at 7:25:00 p.m. ET - Trading Halt: Halt News PendingBenzinga · Jun 1, 2026, 11:25 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock